Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

American Society of Hematology (ASH) 61st Annual Meeting: Orlando, FL, USA, 6–10 December 2019

American Society of Hematology (ASH) 61st Annual Meeting: Orlando, FL, USA, 6–10 December 2019 Targeted Oncology (2020) 15:1–6 https://doi.org/10.1007/s11523-020-00699-w MEE TING REPOR T American Society of Hematology (ASH) 61st Annual Meeting: Orlando, FL, USA, 6–10 December 2019 Martin Chopra Published online: 29 January 2020 © Springer Nature Switzerland AG 2020 1 Introduction A number of agents that target BCMA are in different stages of clinical development, and while initial data had The annual American Society of Hematology (ASH) meet- been presented before the 2019 ASH meeting, this year has ing is the premier event in hematology with almost 30,000 seen an unprecedented number of abstracts in this area. professionals from all subspecialities attending this confer- ence. More than 3000 abstracts across all areas of malignant 2.1 CAR T Cell Therapies and non-malignant hematology were presented at the 2019 meeting, which took place in Orlando. Updated results of CRB-402, a first-in-human study of the With more than 17,000 members from nearly 100 coun- next-generation anti-BCMA CAR T cell therapy bb21217 tries, ASH is the world’s largest professional society serv- in patients with relapsed or refractory (R/R) MM demon- ing both clinicians and scientists around the world who are strated high very good partial response (VGPR) or better working to conquer blood diseases. The Society’s mission rates http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Targeted Oncology Springer Journals

American Society of Hematology (ASH) 61st Annual Meeting: Orlando, FL, USA, 6–10 December 2019

Chopra, Martin
Targeted Oncology , Volume 15 (1) – Feb 29, 2020
Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/american-society-of-hematology-ash-61st-annual-meeting-orlando-fl-usa-VC09l69MP0

References (16)

Publisher
Springer Journals
Copyright
Copyright © Springer Nature Switzerland AG 2020
ISSN
1776-2596
eISSN
1776-260X
DOI
10.1007/s11523-020-00699-w
Publisher site
See Article on Publisher Site

Abstract

Targeted Oncology (2020) 15:1–6 https://doi.org/10.1007/s11523-020-00699-w MEE TING REPOR T American Society of Hematology (ASH) 61st Annual Meeting: Orlando, FL, USA, 6–10 December 2019 Martin Chopra Published online: 29 January 2020 © Springer Nature Switzerland AG 2020 1 Introduction A number of agents that target BCMA are in different stages of clinical development, and while initial data had The annual American Society of Hematology (ASH) meet- been presented before the 2019 ASH meeting, this year has ing is the premier event in hematology with almost 30,000 seen an unprecedented number of abstracts in this area. professionals from all subspecialities attending this confer- ence. More than 3000 abstracts across all areas of malignant 2.1 CAR T Cell Therapies and non-malignant hematology were presented at the 2019 meeting, which took place in Orlando. Updated results of CRB-402, a first-in-human study of the With more than 17,000 members from nearly 100 coun- next-generation anti-BCMA CAR T cell therapy bb21217 tries, ASH is the world’s largest professional society serv- in patients with relapsed or refractory (R/R) MM demon- ing both clinicians and scientists around the world who are strated high very good partial response (VGPR) or better working to conquer blood diseases. The Society’s mission rates

Journal

Targeted Oncology – Springer Journals

Published: Feb 29, 2020

There are no references for this article.